

Medical Policy

Somatuline Depot® (lanreotide)	
MEDICAL POLICY NUMBER	Med_Clin_Ops-058
CURRENT VERSION EFFECTIVE DATE	January 1, 2024
APPLICABLE PRODUCT AND MARKET	<i>Individual Family Plan: All Plans</i> <i>Small Group: All Plans</i> <i>Medicare Advantage: All Plans</i>

Brand New Day/Central Health Medicare Plan develops policies and makes coverage determinations using credible scientific evidence including but not limited to MCG™ Health Guidelines, the ASAM Criteria™, and other third party sources, such as peer-reviewed medical literature generally recognized by the relevant medical community, physician specialty society recommendations, and expert opinion as relevant to supplement those sources. Brand New Day/Central Health Medicare Plan Medical Policies, MCG™ Guidelines, and the ASAM Criteria™ are not intended to be used without the independent clinical judgment of a qualified health care provider considering the individual circumstances of each member's case. The treating health care providers are solely responsible for diagnosis, treatment, and medical advice. Members may contact Brand New Day/Central Health Medicare Plan Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Brand New Day/Central Health Medicare Plan Medical Policy may contact the Health Plan. Brand New Day/Central Health Medicare Plan policies and practices are compliant with federal and state requirements, including mental health parity laws.

If there is a difference between this policy and the member specific plan document, the member benefit plan document will govern. For Medicare Advantage members, Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), govern. Refer to the CMS website at <http://www.cms.gov> for additional information.

Brand New Day/Central Health Medicare Plan medical policies address technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and do not constitute an offer of coverage nor medical advice. Brand New Day/Central Health Medicare Plan medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Brand New Day/Central Health Medicare Plan does not provide health care services and, therefore, cannot guarantee any results or outcomes. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies are updated based on changes in the evidence and healthcare coding and therefore are subject to change without notice. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). MCG™ and Care Guidelines® are trademarks of MCG Health, LLC (MCG).

PURPOSE

To promote consistency between reviewers in clinical coverage decision-making by providing the criteria that generally determine the medical necessity of Somatuline Depot® (lanreotide) therapy.

POLICY/CRITERIA

Prior Authorization and Medical Review is required.

Coverage for Somatulane will be provided for 12 months and may be renewed.

Initial Therapy

1. Individual is 18 years of age or older; **AND**
2. Patient has not received a long-acting somatostatin analogue (e.g., Octreotide LAR, Lanreotide SR, Lanreotide Autogel) within the last 4 weeks; **AND**
3. Diagnosis of **ONE** of the following:

Somatuline Depot

Med_Clin_Ops_058

Medical Policy

- a. **Acromegaly**
 - i. Diagnosis confirmed by elevated (age-adjusted) or equivocal serum IGF-1; **AND**
 - ii. Inadequate suppression of GH after a glucose load; **AND**
 - iii. Prior treatment/assessment of inadequate response to surgery and/or radiotherapy **OR** surgery and/or radiotherapy is not an option; **AND**
 - iv. Baseline growth hormone (GH) and IGF-I blood levels (renewal will require reporting of current levels); **AND**
 - v. Tumor (i.e., growth hormone-secreting pituitary adenoma) is visualized on imaging studies (MRI or CT-scan)
- b. **Carcinoid Syndrome**
 - i. To reduce the frequency of short-acting somatostatin analog rescue therapy; **OR**
 - ii. Treatment and/or control of symptoms
- c. **Neuroendocrine tumor**
 - i. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
 1. Disease is unresectable, locally advanced or metastatic; **AND**
 2. Disease is a non-functioning tumor without hormone-related symptoms; **AND**
 3. Disease is well or moderately differentiated.
 - ii. Any of the following tumors of the GI tract, lung, thymus, or pancreas
 1. Treatment of unresectable primary gastrinoma; **OR**
 2. Treatment of symptoms related to hormone hypersecretion and/or Carcinoid syndrome; **OR**
 3. Tumor control in individuals with unresectable and/or metastatic disease

Background

Somatuline Depot is an octapeptide analog of natural somatostatin, behaves similarly to that of natural somatostatin and inhibits secretion of various endocrine, neuroendocrine, exocrine and paracrine functions; thereby, normalizing growth hormones (GH) and/or insulin-like growth factor-1 (IGF-1) levels in acromegalic patients.

DEFINITIONS

1. SOMATULINE DEPOT (lanreotide) injection, for subcutaneous use. Initial U.S. Approval: 2007
 - a. SOMATULINE DEPOT is supplied in strengths of 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL as a white to pale yellow, semi-solid formulation in a single, sterile, prefilled, ready-to-use, syringe fitted with an automatic safety system

CODING

Applicable NDC Codes	
15054-1120-xx	Somatuline Depot single use subcutaneous solution

Somatuline Depot

Med_Clin_Ops_058

Page 2 of 5

Medical Policy

Applicable Procedure Code	
J1930	Injection, somatuline depot, 1 mg, 1 billable unit = 1 mg

Applicable ICD-10 Codes	
C25	Malignant Neoplasm Of Pancreas, unspecified
C25.0	Malignant Neoplasm Of Head of pancreas
C25.1	Malignant neoplasm of body of pancreas
C25.2	Malignant neoplasm of tail of pancreas
C25.3	Malignant neoplasm of pancreas
C25.4	Malignant neoplasm of endocrine pancreas
C25.7	Malignant neoplasm of other parts of pancreas
C25.8	Malignant neoplasm of overlapping sites of pancreas
C25.9	Malignant neoplasm of pancreas
C37	Malignant neoplasm of thymus
C74	Malignant neoplasm of adrenal gland
C74.0	Malignant neoplasm of cortex of adrenal gland
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland
C74.01	Malignant neoplasm of cortex of right adrenal gland
C74.02	Malignant neoplasm of cortex of left adrenal gland
C74.1	Malignant neoplasm of medulla of adrenal gland
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland
C74.11	Malignant neoplasm of medulla of right adrenal gland
C74.12	Malignant neoplasm of medulla of left adrenal gland
C74.9	Malignant neoplasm of unspecified part of adrenal gland
C74.90	Malignant neoplasm of unspecified part of adrenal gland
C74.91	Malignant neoplasm of unspecified part of left adrenal gland
C74.92	Malignant neoplasm of unspecified part of left adrenal gland
C7A	Malignant neuroendocrine tumors
C7A.0	Malignant carcinoid tumors
C7A.00	Malignant carcinoid tumor of unspecified site
C7A.01	Malignant carcinoid tumors of the small intestine
C7A.010	Malignant carcinoid tumor of the duodenum
C7A.011	Malignant carcinoid tumor of the jejunum
C7A.012	Malignant carcinoid tumor of the ileum
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.02	Malig carcinoid tumors of the appendix, large intestine, and rectum
C7A.020	Malignant carcinoid tumor of the appendix
C7A.021	Malignant carcinoid tumor of the cecum
C7A.022	Malignant carcinoid tumor of the ascending colon
C7A.023	Malignant carcinoid tumor of the transverse colon
C7A.024	Malignant carcinoid tumor of the descending colon
C7A.025	Malignant carcinoid tumor of the sigmoid colon
C7A.026	Malignant carcinoid tumor of the rectum
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion
C7A.09	Malignant carcinoid tumors of other sites
C7A.090	Malignant carcinoid tumor of the bronchus and lung

Somatuline Depot

Med_Clin_Ops_058

Medical Policy

C7A.091	Malignant carcinoid tumor of the thymus
C7A.092	Malignant carcinoid tumor of the stomach
C7A.093	Malignant carcinoid tumor of the kidney
C7A.094	Malignant carcinoid tumor of the foregut, unspecified
C7A.095	Malignant carcinoid tumor of the midgut, unspecified
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified
C7A.098	Malignant carcinoid tumors of other sites
C7A.1	Malignant poorly differentiated neuroendocrine tumors
C7A.8	Other malignant neuroendocrine tumors
C7B	Secondary neuroendocrine tumors
C7B.0	Secondary carcinoid tumors
C7B.00	Secondary carcinoid tumors, unspecified site
C7B.01	Secondary carcinoid tumors of distant lymph nodes
C7B.02	Secondary carcinoid tumors of liver
C7B.03	Secondary carcinoid tumors of bone
C7B.04	Secondary carcinoid tumors of peritoneum
C7B.09	Secondary carcinoid tumors of other sites
C7B.1	Secondary merkel cell carcinoma
C7B.8	Other secondary neuroendocrine tumors
D13.7	Benign neoplasm of endocrine pancreas
D15.0	Benign neoplasm of thymus
D35.2	Benign neoplasm of pituitary gland
D35.3	Benign neoplasm of craniopharyngeal duct
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified
D3A	Benign neuroendocrine tumors
D3A.0	Benign carcinoid tumors
D3A.00	Benign carcinoid tumor of unspecified site
D3A.01	Benign carcinoid tumors of the small intestine
D3A.010	Benign carcinoid tumor of the duodenum
D3A.011	Benign carcinoid tumor of the jejunum
D3A.012	Benign carcinoid tumor of the ileum
D3A.019	Benign carcinoid tumor of the small intestine, unspecified portion
D3A.02	Benign carcinoid tumors of the appendix, large intestine, and rectum
D3A.020	Benign carcinoid tumor of the appendix
D3A.021	Benign carcinoid tumor of the cecum
D3A.022	Benign carcinoid tumor of the ascending colon
D3A.023	Benign carcinoid tumor of the transverse colon
D3A.024	Benign carcinoid tumor of the descending colon
D3A.025	Benign carcinoid tumor of the sigmoid colon
D3A.026	Benign carcinoid tumor of the rectum
D3A.029	Benign carcinoid tumor of the large intestine, unspecified portion
D3A.09	Benign carcinoid tumors of other sites
D3A.090	Benign carcinoid tumor of the bronchus and lung
D3A.091	Benign carcinoid tumor of the thymus
D3A.092	Benign carcinoid tumor of the stomach
D3A.093	Benign carcinoid tumor of the kidney

Somatuline Depot

Med_Clin_Ops_058

Medical Policy

D3A.094	Benign carcinoid tumor of the foregut, unspecified
D3A.095	Benign carcinoid tumor of the midgut, unspecified
D3A.096	Benign carcinoid tumor of the hindgut, unspecified
D3A.098	Benign carcinoid tumors of other sites
D3A.8	Other benign neuroendocrine tumors
E16.1	Other hypoglycemia
E16.3	Increased secretion of glucagon
E16.4	Increased secretion of gastrin
E16.8	Other specified disorders of pancreatic internal secretion
E22.0	Acromegaly and pituitary gigantism
E24.8	Other cushing's syndrome
E34.0	Carcinoid syndrome
Z85.020	Personal history of malignant carcinoid tumor of stomach
Z85.030	Personal history of malignant carcinoid tumor of large intestine
Z85.040	Personal history of malignant carcinoid tumor of rectum
Z85.060	Personal history of malignant carcinoid tumor of small intestine
Z85.07	Personal history of malignant neoplasm of pancreas
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung
Z85.230	Personal history of malignant carcinoid tumor of thymus
Z85.858	Personal history of malignant neoplasm of other endocrine glands

EVIDENCE BASED REFERENCES

1. Product Information: SOMATULINE(R) solution for IM injection, lanreotide acetate solution for IM injection. Tercica Inc., Brisbane, CA, 2011.

POLICY HISTORY

Original Effective Date	May 24, 2021
Revised Date	November 1, 2021: Annual review – no changes made. November 8, 2022: Annual review – no changes made. March 1, 2023: Adopted by MA UM Committee – no changes made. January 1, 2024 - Updated to Brand New Day/Central Health Medicare Plan (no policy revisions made)

Approved by Pharmacy and Therapeutics Committee on 11/8/2022